# Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers

> **NCT02924155** · PHASE1 · COMPLETED · sponsor: **Samjin Pharmaceutical Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SJP002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02924155
- **Lead sponsor:** Samjin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-05
- **Primary completion:** 2016-11-17
- **Final completion:** 2016-11-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924155, "Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02924155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*